Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Stephen Lim"'
Publikováno v:
Journal of Clinical Oncology. 39:e19551-e19551
e19551 Background: The AE rates and HRU reported in multiple real-world evidence (RWE) studies of chimeric antigen receptor T-cell (CAR-T) therapies tisa-cel and axi-cel in r/r DLBCL have differed from those in their clinical trials. However, the cos
Autor:
Jing Zhao, Stephen Lim, Vamsi Bollu, Hongbo Yang, Qiufei Ma, Angela Lax, Mimi Tesfaye, Anand A. Dalal
Publikováno v:
Journal of Clinical Oncology. 39:e19550-e19550
e19550 Background: Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are CAR-T therapies that were approved for r/r DLBCL in 2017 and 2018, respectively. While majority of the CAR-T infusions occur at inpatient (IP) setting in clinica
Autor:
Carley Turner, Laura Stampleman, Armando Sanchez, Shahrooz Eshaghian, Robert A. Moss, Ravindranath Patel, Youram Nassir, Stephen Lim, Gary T. Schwartz, Benjamin Eades, Jennifer To, Daisy Martinez, Robert Vescio, Tanya M. Spektor, Matthew Ghermezi, Regina A. Swift, James R. Berenson, Alberto Bessudo
Publikováno v:
Journal of Clinical Oncology. 37:8048-8048
8048 Background: Preclinical studies from our laboratory have demonstrated that ruxolitinib (RUX) in combination with lenalidomide (LEN) and dexamethasone shows marked anti-myeloma effects both in vitro and in vivo. Furthermore, MUC1 is responsible f
Autor:
Regina A. Swift, Robert Vescio, James R. Berenson, Robert A. Moss, Jennifer To, Tanya M. Spektor, Stephen Lim, Benjamin Eades, Gary T. Schwartz, Carley Turner, Shahrooz Eshaghian, Laura Stampleman
Publikováno v:
Journal of Clinical Oncology. 36:8005-8005
8005Background: Preclinical studies from our laboratory have demonstrated that ruxolitinib (RUX) in combination with lenalidomide (LEN) and dexamethasone shows marked anti-myeloma effects both in vitro and in vivo. Furthermore, MUC1 is responsible fo
Autor:
Tanya M. Spektor, Steven Jeffrey Hager, Mehdi M. Moezi, Robert A. Moss, Stephen Lim, Shahrooz Eshaghian, Alan Cartmell, Joseph Z. Ye, Tina Maluso, Alberto Bessudo, Regina A. Swift, G. Q. Chen, James R. Berenson, Jacob D. Bitran, Alexa Cohen, Teresa A. Coleman, John Stewart Hrom
Publikováno v:
Journal of Clinical Oncology. 35:8013-8013
8013 Background: The proteasome inhibitor (PI) ixazomib (Ixz) is the first orally administered PI approved for treating multiple myeloma (MM). It has shown clinical activity as a single agent and when used in other combinations. In this phase 1/2 tri
Publikováno v:
Journal of Clinical Oncology. 29:6578-6578
6578 Background: Myeloablative hematopoietic cell transplant (HCT) for leukemia/lymphoma is highly toxic and often not well tolerated. Total lymphoid irradiation and antithymocyte globulin (TLI-ATG...